ANI PHARMACEUTICALS INC·4

Mar 10, 4:06 PM ET

Davis Krista 4

Research Summary

AI-generated summary

Updated

ANI Pharmaceuticals (ANIP) SVP Krista Davis Sells Shares

What Happened Krista Davis, SVP & Chief HR Officer of ANI Pharmaceuticals (ANIP), sold a total of 6,572 shares in two open-market transactions in March 2026 for combined gross proceeds of about $488,474. On 2026-03-06 she sold 1,485 shares at $75.00 each for $111,375. On 2026-03-09 she sold 5,087 shares at a weighted average price of $74.13 (individual trades ranged $72.94–$74.76) for $377,099. These were sales (dispositions) reported on a Form 4 filed 2026-03-10.

Key Details

  • Transaction dates/prices:
    • 2026-03-06: 1,485 shares @ $75.00 = $111,375
    • 2026-03-09: 5,087 shares @ weighted avg $74.13 (range $72.94–$74.76) = $377,099
  • Total: 6,572 shares sold for ~$488,474.
  • Method/code: Open market or private sale (Code S — sale/disposition).
  • Footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted 2025-09-18; second sale comprised multiple trades (weighted avg reported).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Filing timeliness: Form 4 was filed 2026-03-10; this is timely for the reported trade dates.

Context These sales were executed under a pre-established 10b5‑1 plan, which typically means the trades followed a preset schedule and are often routine rather than a direct statement about the insider’s current view of the company. For retail investors, purchases usually carry more signal about insider confidence; sales can be for many personal or diversification reasons and are not, by themselves, a clear bearish indicator.